When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ZLAB - Incyte PD-1 inhibitor shows benefit in mid-stage anal cancer study
Zai Lab Limited
A 94-subject Phase 2 clinical trial, PODIUM-202, evaluating Incyte's (NASDAQ:INCY) PD-1 inhibitor retifanlimab (formerly INCMGA0012) in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed after platinum-based chemo showed a treatment benefit. The results are available on demand at ESMO.
More news on: Incyte Corporation, MacroGenics, Inc., Zai Lab Limited, Healthcare stocks news,